Development
Takeda Pharmaceutical Company Limited
TAK
$15.30
-$0.22-1.42%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 716.24M | -332.48M | 651.35M | 235.35M | 844.95M |
| Total Depreciation and Amortization | 1.27B | 1.26B | 1.25B | 1.03B | 1.25B |
| Total Amortization of Deferred Charges | -- | -- | -- | 193.22M | -- |
| Total Other Non-Cash Items | 133.41M | -34.55M | 364.98M | -319.33M | 219.30M |
| Change in Net Operating Assets | -1.12B | 479.23M | -1.59B | 1.08B | 363.89M |
| Cash from Operations | 992.19M | 1.38B | 673.25M | 2.22B | 2.68B |
| Capital Expenditure | -318.96M | -261.99M | -334.85M | -270.39M | -237.36M |
| Sale of Property, Plant, and Equipment | 1.81M | 57.64M | 80.10K | 6.67M | -120.60K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00 | -48.50K | 2.71M | 60.16M | -- |
| Other Investing Activities | -192.79M | -214.94M | -1.61B | -3.11B | -93.68M |
| Cash from Investing | -509.94M | -419.35M | -1.94B | -3.31B | -331.17M |
| Total Debt Issued | 170.00B | 0.00 | 210.00B | 115.00B | -- |
| Total Debt Repaid | -96.51B | -157.07B | -110.63B | -85.98B | -266.20B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | 0.00 | 0.00 | -2.33B | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -936.64M | -62.75M | -952.65M | -78.76M | -914.91M |
| Other Financing Activities | -33.00B | 25.48B | -24.07B | -25.21B | -39.77B |
| Cash from Financing | -662.32M | -973.66M | -420.98M | -49.89M | -3.09B |
| Foreign Exchange rate Adjustments | -21.10M | 27.69M | 107.54M | -1.60M | -67.94M |
| Miscellaneous Cash Flow Adjustments | 13.60K | 0.00 | -7.30K | -- | -7.10K |
| Net Change in Cash | -201.15M | 11.57M | -1.58B | -1.15B | -801.46M |